DJIA 18,011.78 -0.16 0.00%
NASDAQ 5,088.43 11.90 0.23%
S&P 500 2,113.41 3.81 0.18%
market minute promo

Pfizer (NYSE: PFE)

34.49 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

PFE $34.48 -0.03%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $34.55
Previous Close $34.49
Daily Range $34.46 - $34.66
52-Week Range $27.51 - $35.53
Market Cap $212.4B
P/E Ratio 23.95
Dividend (Yield) $1.12 (3.2%)
Ex-Dividend Date
Dividend Pay Date
Volume 904,099
Average Daily Volume 24,005,034
Current FY EPS $2.04




Drug Makers

Pfizer (PFE) Description

A research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra. Website:

News & Commentary Rss Feed

Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.

AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.

Pre-Market Laggard: Pfizer (PFE)

Pfizer's (PFE) Management Reviews Oncology Business and ASCO Data Presentations (Transcript)

Why Health Care Stocks Will Continue to Lead Market Higher

Health care companies see $ signs as Baby Boomers age

Health care companies see dollar signs as Baby Boomers get older

Dow Jones (DJIA) Today: Pfizer (PFE) Lower

Pfizer's Monstrous Clinical Pipeline Is Harboring 2 Hidden Gems

Pfizer's mind-boggling size often results in promising clinical candidates getting swept under the rug, so to speak. Here is a look at two of the pharma giant's orphan drug candidates that haven't generated much talk among investors, despite being potential game-changers for their target indications.

10 American Companies That Pull in the Most Cash

Let's measure something that's better than "profitability."

Viagra Maker Pfizer Keeps Boosting Dividends

4 Stocks Eagle Asset Management Has Been Buying

It can pay off to keep an eye on what the big investors are doing.

See More PFE News...

PFE's Top Competitors

PFE $34.49 (0.00%)
Current stock: PFE
JNJ $100.13 (0.15%)
Current stock: JNJ
ROG $73.59 (1.15%)
Current stock: ROG
GSK $44.14 (-0.23%)
Current stock: GSK